Russia's Nanolek working on exporting HPV vaccine to CIS countries, North Africa, Mongolia, Nicaragua, Vietnam

KIROV. May 19 (Interfax) - The launch of a second antigen production site for the human papillomavirus vaccine will allow Nanolek to begin exporting, the company's director for government relations and market access Valentin Dodonov said.

As reported, the company launched the first production line for the HPV vaccine in October 2025, with a capacity of at least 600,000 doses per year. The investment amounted to 7.5 billion rubles, of which 950 million rubles was a preferential loan from the Industrial Development Fund. By 2027, Nanolek plans to launch a second line, as a result of which the total annual capacity of the facility for vaccine production will exceed 3 million doses.

"First and foremost, our export supplies are aimed at friendly countries - the CIS [Commonwealth of Independent States] countries. As part of the EAEU [Eurasian Economic Union] registration procedure, in the coming year we plan to send supplies to Belarus, Kazakhstan, Armenia and Kyrgyzstan. We are currently working on the possibility of supplies to Mongolia, and we are already at the stage of concluding a cooperation agreement. We also recently had a meeting with Egypt - this concerns not only supplies to Egypt but also to North Africa. There was also a meeting with Nicaragua, where there is very strong interest not only in the HPV vaccine but also in all our developments. The HPV vaccine is of interest to Vietnam," he said.

At the same time, the company's priority is meeting domestic demand within Russia, Dodonov said.

Nanolek is a biopharmaceutical company founded in 2011. Its portfolio includes drugs for the prevention of whooping cough, diphtheria, tetanus, polio, as well as Haemophilus influenzae type b, meningococcal and pneumococcal infections. The production complex in the Kirov region can produce up to 10 million pre-filled syringes, 8 million vials of solutions and suspensions, 1 million vials of lyophilized products and 2 billion tablets per year.